[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"blood-pressure\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:blood-pressure":29},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,112,0,25,[9,51,83,122,147,170,210,241,265,289,312,338,357,378,391,416,436,454,479,498,531,558,585,612,642],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":31,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":39,"lastUpdatePostDateStruct":40,"startDateStruct":43,"completionDateStruct":45,"leadSponsor":47,"locationsCount":50},"100462703","tscs-for-acute-sci-100462703",false,"NCT05305118","TSCS for Acute SCI","Safety, Feasibility, and Efficacy of Transcutaneous Spinal Cord Stimulation on Stabilizing Blood Pressure for Acute Inpatients With Spinal Cord Injury","Inclusion Criteria:\n\n* All newly injured patients with SCI who are sequentially admitted during the 42-month recruitment period\n* Meet the following Model Systems entry criteria with evidence of BP instability\n* Exhibit one or more of the following: Resting hypotension - systolic BP ≤ 110 mmHg for males or ≤ 100 mmHg for females; OH - fall in systolic BP ≥ 20 mmHg and\u002For a fall in diastolic BP ≥ 10 mmHg within 10 minutes of assuming an upright position; BP instability - fluctuation in systolic BP ≥ 20 mmHg and\u002For fluctuation in diastolic BP ≥ 10 mmHg within a single day during routine activities in the AIR setting.\n* Have trouble with your blood pressure as determined by your doctor.\n* Participants must be between the ages of 18-89 years old, experienced a spinal cord injury (SCI) within the past 30 days to 6 months, have sustained a SCI with temporary or permanent loss of sensory and\u002For motor function, and are an inpatient for acute SCI rehabilitation therapy at Mount Sinai.\n* You are not dependent on a ventilator at this time.\n* You do not have a history of implanted pacemaker\u002Fdefibrillator or significant coronary artery disease.\n\nExclusion Criteria:\n\n* Implanted brain\u002Fspine\u002Fnerve stimulators, cochlear implants, cardiac pacemaker\u002Fdefibrillator, or intracardiac lines\n* Open skin lesions on or near the electrode placement sites (neck, upper back)\n* Significant coronary artery or cardiac conduction disease\n* Recent history of myocardial infarction\n* Insufficient mental capacity to understand and independently provide consent\n* Pregnancy\n* Cancer\n* Deemed unsuitable by study physician\n\nAs part of the feasibility assessment, the study team will document demographic and injury characteristics of eligible patients who refuse enrollment, as well as reasons for ineligibility among those who do not meet entrance criteria.","ALL","18 Years","89 Years",{"count":21,"type":22},50,"ESTIMATED","INTERVENTIONAL",[25],"NA","This project will focus on a novel approach to stabilizing blood pressure (BP) during inpatient rehabilitation after acute SCI. After SCI, people have unstable blood pressure, ranging from too low (orthostatic hypotension) to too high (autonomic dysreflexia). Unstable BP often interferes with performing effective physical rehabilitation after SCI. A critical need exists for the identification of safe, practical and effective treatment options that stabilize BP after traumatic SCI. Transcutaneous Spinal Cord Stimulation (TSCS) has several advantages over pharmacological approaches: (1) does not exacerbate polypharmacy, (2) can be activated\u002Fdeactivated rapidly, and (3) can be applied in synergy with physical exercise. The study team is asking the key question: \"What if applying TSCS earlier after injury could prevent the development of BP instability?\" To facilitate adoption of TSCS for widespread clinical use, the study team plans to map and develop a parameter configuration that will result in an easy to follow algorithm to maximize individual benefits, while minimizing the burden on healthcare professionals. This project will provide the foundational evidence to support the feasible and safe application of TSCS in the newly injured population, thereby overcoming barriers to engagement in prescribed inpatient rehabilitation regimens that are imposed by BP instability.",[28,29,30],"Acute Spinal Cord Injury","Blood Pressure","Hypotension",[32,33,34,35,36,37],"Transcutaneous Spinal Cord Stimulation","Neuromodulation","Spinal Cord Stimulation","Blood Pressure Disorders","Cerebral Blood Flow Velocity","Acute Inpatient Rehabilitation","RECRUITING","2026-08-20",{"date":41,"type":42},"2026-08-24","ACTUAL",{"date":44,"type":42},"2022-03-18",{"date":46,"type":22},"2027-01-12",{"name":48,"class":49},"Icahn School of Medicine at Mount Sinai","OTHER",1,{"id":52,"slug":53,"hasResults":12,"nctId":54,"briefTitle":55,"officialTitle":56,"acronym":57,"eligibilityCriteria":58,"healthyVolunteers":59,"sex":17,"minAge":60,"maxAge":61,"enrollmentInfo":62,"targetDuration":4,"studyType":23,"phases":64,"briefSummary":65,"conditions":66,"keywords":71,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":74,"lastUpdatePostDateStruct":75,"startDateStruct":77,"completionDateStruct":79,"leadSponsor":81,"locationsCount":50},"100582854","ketone-ester-and-salt-keas-in-older-adults-100582854","NCT06868719","Ketone Ester And Salt (KEAS) in Older Adults","Ketone Supplementation as a Strategy to Reduce the Negative Health Effects of High Dietary Salt in Older Adults","KEAS-O","Inclusion Criteria:\n\n* Between the ages of 60-85\n* Resting blood pressure no higher than 150\u002F90\n* BMI below 35 kg\u002Fm2 (or otherwise healthy)\n* Free of any metabolic disease (diabetes or renal), pulmonary disorders (COPD, severe asthma, or cystic fibrosis), cardiovascular disease (peripheral vascular, cardiac, or cerebrovascular)\n* Do not have any precluding medical conditions that prevent participants from exercising (i.e., cardiovascular issues, or muscle\u002Fjoint issues including painful arthritis) or giving blood (e.g., blood thinners)\n\nExclusion Criteria:\n\n* High blood pressure - greater than150\u002F90 mmHg\n* Obesity (BMI \\> 30 kg\u002Fm2)\n* History of metabolic disease (diabetes or renal disease), pulmonary disorders (e.g., COPD, severe asthma, \\& cystic fibrosis), and cardiovascular disease (peripheral vascular, cardiac, or cerebrovascular).\n* Medical issues that prevent safe exercise (i.e., cardiovascular issues, or muscle\u002Fjoint issues including painful arthritis)\n* Medical issues that prevent giving blood (e.g., blood thinners).\n* Current smoking, using smokeless tobacco, or vaping (within past 12 months)\n* Current pregnancy",true,"50 Years","85 Years",{"count":63,"type":22},35,[25],"Most Americans consume excess dietary salt based on the recommendations set by the American Heart Association and Dietary Guidelines for Americans. High dietary salt impairs blood pressure control by affecting systemic blood vessels and the kidneys. These changes contribute to excess salt consumption being associated with increased risk for chronic kidney disease and cardiovascular disease, the leading cause of death in America. Salt is particularly deleterious in older adults who are more likely to exhibit salt-sensitive hypertension. However, salt consumption remains high in the United States. Thus, there is a critical need for strategies to counteract the effects of high dietary salt as consumption is likely not going to decrease. One promising option is ketones, metabolites that are produced in the liver during prolonged exercise and very low-calorie diets. While exercise and low-calorie diets are beneficial, not many people engage in these activities. Limited evidence indicates that ketone supplements improve cardiovascular health in humans. Additionally, published rodent data indicates that ketone supplements prevent high salt-induced increases in blood pressure, blood vessel dysfunction, and kidney injury. Our human pilot data also indicates that high dietary salt reduces intrinsic ketone production, but it is unclear whether ketone supplementation confers humans' protection against high salt similar to rodents. Therefore, the investigators seek to conduct a short-term high-dietary salt study to determine whether ketone supplementation prevents high dietary salt from eliciting increased blood pressure, blood vessel dysfunction, and kidney injury\u002Fimpaired blood flow. The investigators will also measure inflammatory markers in blood samples and isolate immune cells that control inflammation. Lastly, the investigators will also measure blood ketone concentration and other circulating metabolites that may be altered by high salt, which could facilitate novel therapeutic targets to combat high salt.",[67,68,69,70,29],"Salt; Excess","Hypertension","Aging","Inflammation",[29,72,69,70,73],"Salt","Cardiovascular Disease","2026-08-18",{"date":76,"type":42},"2026-08-19",{"date":78,"type":42},"2025-03-06",{"date":80,"type":22},"2027-12-31",{"name":82,"class":49},"Indiana University",{"id":84,"slug":85,"hasResults":12,"nctId":86,"briefTitle":87,"officialTitle":88,"acronym":89,"eligibilityCriteria":90,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":91,"targetDuration":4,"studyType":23,"phases":93,"briefSummary":94,"conditions":95,"keywords":99,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":111,"lastUpdatePostDateStruct":112,"startDateStruct":114,"completionDateStruct":116,"leadSponsor":118,"locationsCount":121},"100611457","accuracy-of-a-cuffless-photoplethysmography-ppg-chest-patch-monitor-for-24-hour-ambulatory-blood-pressure-monitoring-abpm-100611457","NCT07240831","Accuracy of a Cuffless Photoplethysmography (PPG) Chest-Patch Monitor for 24-hour Ambulatory Blood Pressure Monitoring (ABPM)","Accuracy of a Cuffless Photoplethysmography (PPG) Chest-Patch Monitor for 24-hour Ambulatory Blood Pressure Monitoring","PPG ABPM","Inclusion Criteria\n\n* Females and Males subjects 18 years or older (from all skin tones\u002Fcolors)\n* Scheduled for ABPM for hypertension screening, evaluation, or management\n* Subjects capable of using an application temporarily downloaded (for the duration of the study) on a personal smart phone device or on a device provided by the study sponsor\n* Subjects with Atrial fibrillation or Atrial flutter are eligible to participate if standard cuff-based ABPM monitor can capture blood pressure at initialization\n\nExclusion Criteria\n\n* Indication for ABPM is orthostatic hypotension or Postural Orthostatic Tachycardiac Syndrome as indicated on the ABPM referral order\n* Any neurological, psychological, or other condition impairing the ability to provide informed consent or participate in the study\n* Inability to reliably access the Internet via a smart phone\n* Not able to perform standard cuff-based ABPM\n* Average absolute difference between the two arms is greater than 15 mmHg for Systolic Blood Pressure (SBP) or greater than 10 mmHg Diastolic Blood Pressure (DBP) during the initialization\u002Fcalibration phase\n* Subjects with known allergy to adhesives or skin patches\n* Subjects with solid dark tattoos on the area where the PPG-based device is attached\n* Subjects who are unwilling to have their chest hair shaved, if needed, to install the device (the device uses adhesives and needs to be in direct contact with the skin without hair)\n* Subjects who are unwilling to comply with the study instructions (avoid vigorous exercise and showering for 24 hours while the device is in place)",{"count":92,"type":22},600,[25],"This study aims to validate the accuracy and reliability of blood pressure (BP) estimates obtained over 24 hours using a PPG-based chest-patch device compared to the gold standard ambulatory blood pressure monitoring (ABPM) method using an upper arm cuff-based oscillometric BP device, in both hypertensive and normotensive individuals referred by their provider to undergo a 24-hours ABPM for clinical indication. The Awake\u002FAsleep test, which is the primary test recommended for automated wearable cuffless BP devices that are cuff-calibrated (based on the 2023 European Society of Hypertension (ESH) recommendations for the validation of cuffless blood pressure measuring devices), will be conducted in this study. The secondary aim of the study is to assess the feasibility and convenience of the PPG-based device.",[29,96,97,98],"Heart Disease","Hypertension (HTN)","Blood Pressure Monitoring",[100,101,97,102,103,104,105,106,107,108,109,110],"BLOOD PRESSURE","BLOOD PRESSURE MONITORING","CUFFLESS PHOTOPLETHYSMOGRAPHY","PPG","CUFFLESS","vital signs","ABPM","24 hour ABPM","Ambulatory Blood Pressure Monitoring","Ambulatory Blood Pressure","BP","2026-08-11",{"date":113,"type":42},"2026-08-13",{"date":115,"type":42},"2025-12-15",{"date":117,"type":22},"2026-10-30",{"name":119,"class":120},"Biobeat Technologies Ltd.","INDUSTRY",11,{"id":123,"slug":124,"hasResults":12,"nctId":125,"briefTitle":126,"officialTitle":126,"acronym":4,"eligibilityCriteria":127,"healthyVolunteers":59,"sex":17,"minAge":18,"maxAge":128,"enrollmentInfo":129,"targetDuration":4,"studyType":23,"phases":131,"briefSummary":132,"conditions":133,"keywords":4,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":137,"lastUpdatePostDateStruct":138,"startDateStruct":140,"completionDateStruct":142,"leadSponsor":144,"locationsCount":50},"100645763","ai-guided-predictions-of-blood-pressure-dysregulation-using-perfusion-index-as-a-novel-biomarker-in-persons-with-spinal-cord-injury-100645763","NCT07699094","AI-Guided Predictions of Blood Pressure Dysregulation Using Perfusion Index as a Novel Biomarker in Persons With Spinal Cord Injury","Inclusion Criteria:\n\n* The participant had a spinal cord injury (SCI: C4-T12) for more than one year and the SCI was graded as ASIA Impairment Scale (AIS) A or B (unable to voluntarily move your legs)\n* The participant can also be a gender and age-matched (±5 years) able-bodied (AB) control subject (similar gender and age to a subject with SCI).\n* Subjects with SCI and AB controls must be between 18 and 75 years of age.\n* If the participant are going to do the study, they must avoid caffeine and alcohol, maintain normal salt and water intake, and avoid strenuous exercise for 24 hours prior to the study visit.\n\nExclusion Criteria:\n\n* The participant has cardiovascular, kidney, or untreated thyroid disease\n* The participant has had a traumatic brain injury (TBI)\n* The participant has diabetes mellitus\n* The participant has an acute illness or infection\n* The participant is dehydrated\n* The participant smokes\n* The participant is pregnant\n* The participant has broken, inflamed, or otherwise fragile skin\n* The participant's Body Mass Index (BMI) is more than 30 kg\u002Fm2","75 Years",{"count":130,"type":22},24,[25],"The goal of this clinical trial is to determine if perfusion index (PI) can reliably predict changes in systolic blood pressure (SBP) in persons with spinal cord injury (SCI) during a cool temperature challenge. Participants with SCI can be 18-75 years of age, male or female, neurological level of injury C4-T12, ASIA Impairment Scale (AIS: A or B: motor complete) or gender and healthy age-matched able-bodied (AB) controls.\n\nThe main question this study aims to answer is: can PI reliably predict change in SBP during a cool temperature challenge? The investigators hypothesize that PI can be used as a biomarker of SBP in persons with SCI.\n\nResearchers will compare the relationship of 1) changes in PI and SBP and 2) relationship of changes in other vital signs to SBP, during the cool temperature challenge. The researchers aim to determine if PI can be used as a biomarker of SBP in persons with SCI during a cool temperature challenge (experimental group\u002Farm). Able-bodied controls (control group\u002Farm) will receive the same intervention (cool challenge) as the experimental group.\n\nDuring the study, participants will be asked to wear only shorts and a T-shirt so that their skin can be exposed to the warm and cool temperatures of the 2 rooms.\n\nThe investigators will put put on non-invasive sensors (taped or attached on the surface of your body) to measure PI, BP, and other vital signs. The investigators will record these measurements while the participant is seated in a wheelchair for 10 minutes in a warm room and up to 90 minutes in a cool room.",[134,29,135,136],"Spinal Cord Injuries (SCI)","Thermoregulation","Perfusion Index","2026-08-06",{"date":139,"type":42},"2026-08-10",{"date":141,"type":22},"2026-09-01",{"date":143,"type":22},"2028-06-30",{"name":145,"class":146},"James J. Peters Veterans Affairs Medical Center","FED",{"id":148,"slug":149,"hasResults":12,"nctId":150,"briefTitle":151,"officialTitle":151,"acronym":4,"eligibilityCriteria":152,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":153,"targetDuration":4,"studyType":23,"phases":155,"briefSummary":156,"conditions":157,"keywords":159,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":137,"lastUpdatePostDateStruct":163,"startDateStruct":164,"completionDateStruct":166,"leadSponsor":168,"locationsCount":50},"100482044","therapeutic-mechanisms-of-epidural-spinal-cord-stimulation-100482044","NCT05556902","Therapeutic Mechanisms of Epidural Spinal Cord Stimulation","Inclusion Criteria:\n\n1. Male or Female, age 18-89\n2. Chronic pain for more than 3 months\n3. Willing to visit a research lab\n4. Willing to undergo a blood draw\n5. Able to provide written informed consent\n\nExclusion Criteria\n\n1. History of neurological disease (e.g., dementias, Parkinson's)\n2. History of stroke\n3. Current diagnosis of cancer\n4. Subject is unwilling or unable to comply with the protocol",{"count":154,"type":22},80,[25],"The purpose of this study in patients undergoing routine care epidural spinal cord stimulation (SCS) is to determine 1) whether SCS reduces arterial blood pressure (BP) in patients which chronic low back pain and hypertension, 2) whether higher baseline BP (i.e., hypertension) predicts reductions in pain following SCS, and finally 3) whether different SCS waveforms elicits stimulus-evoked compound action potentials (ECAPs) in spinal cord and at the cortex (electroencephalography, and magnetoenchphalography).",[29,158,68],"Low Back Pain",[34,160,161,162],"Epidural Spinal Cord Stimulation","SCS","Arterial Blood Pressure",{"date":111,"type":42},{"date":165,"type":42},"2022-08-02",{"date":167,"type":22},"2030-05-01",{"name":169,"class":49},"University of Alabama at Birmingham",{"id":171,"slug":172,"hasResults":12,"nctId":173,"briefTitle":174,"officialTitle":175,"acronym":176,"eligibilityCriteria":177,"healthyVolunteers":12,"sex":17,"minAge":178,"maxAge":128,"enrollmentInfo":179,"targetDuration":4,"studyType":23,"phases":181,"briefSummary":182,"conditions":183,"keywords":193,"overallStatus":201,"whyStopped":4,"lastUpdateSubmitDate":202,"lastUpdatePostDateStruct":203,"startDateStruct":204,"completionDateStruct":205,"leadSponsor":207,"locationsCount":209},"100643083","effectiveness-of-neomayor-in-improving-cardiovascular-health-in-chilean-older-adults-100643083","NCT07633392","Effectiveness of NeoMayor in Improving Cardiovascular Health in Chilean Older Adults","A Hybrid Type 1 Effectiveness-Implementation Randomized Controlled Trial of NeoMayor, a Mobile Health Intervention to Improve Cardiovascular Health in Chilean Older Adults","NEOMAYOR","Inclusion criteria\n\n* Age between 55 and 75 years\n* Able to read and understand written instructions\n* Ownership of a smartphone and ability to use it independently\n* Physically inactive, defined as performing less than 30 minutes of daily physical activity or less than 2,5 h a week.\n* Intermediate or high cardiovascular risk, defined as the presence of at least three of the following: Hypertension (history diagnosed by specialist or general practitioner or ≥ 140 mmHg systolic or ≥90 mm Hg diastolic blood pressure at baseline or current antihypertensive treatment);Diabetes Mellitus (history diagnosed by specialist or general practitioner or fasting blood glucose ≥126 mg\u002FdL or current pharmacologic treatment);Obesity (BMI ≥30 kg\u002Fm²); Dyslipidaemia (history diagnosed by specialist or general practitioner or lipid-lowering drugs or baseline total cholesterol ≥ 200 mg\u002FdL or LDL cholesterol ≥100 mg\u002FdL).\n\nExclusion Criteria\n\n* Dementia defined as a score in the MEFO \\\u003C 9\n* Significant limitations for independent mobility, including use of assistive devices, frailty, gait instability, or lower-limb painful conditions limiting physical activity\n* Uncorrected hearing or visual impairment preventing adequate use of a smartphone\n* Chronic neurological, psychiatric, or psychological disorders without regular treatment or follow-up.\n* Present severe alcohol or illicit drug use.\n* Severe or terminal illness","55 Years",{"count":180,"type":22},240,[25],"This study aims to evaluate the effectiveness of NeoMayor, a mobile health (mHealth) intervention designed to improve cardiovascular health among older adults at elevated cardiovascular risk in Chile. NeoMayor is a smartphone-based application that provides personalized guidance on physical activity, diet, sleep, and mental well-being through a multidomain lifestyle approach.\n\nThis multicenter randomized controlled trial will enroll community-dwelling older adults aged 55 to 75 years recruited from primary healthcare centers in urban and rural settings. Participants will be randomized in a 2:1 ratio to either the NeoMayor intervention or a control group receiving standard health information and usual care. The intervention duration will be four months.\n\nThe primary objective is to determine whether the NeoMayor intervention improves cardiovascular health as measured by the Life's Essential 8 Cardiovascular Health Index. Secondary objectives include evaluating changes in cognitive performance, depressive symptoms, anxiety symptoms, quality of life and physical performance outcomes. The study will also assess feasibility and adherence to digital intervention.",[184,185,186,187,188,189,29,190,191,192],"Cardiovascular Health Status","Smoking Status","Physical Activity","Diet Quality","Sleep Duration","Body Mass Index","LDL Cholesterol","Fasting Glucose","Urinary Albumin-to-Creatinine Ratio",[194,195,196,197,198,199,200],"Cardiovascular Health Index","cardiovascular risk","Life's Essential 8","mhealth","older adults","implementation science","hybrid effectiveness-implementation trial","NOT_YET_RECRUITING","2026-08-05",{"date":139,"type":42},{"date":141,"type":22},{"date":206,"type":22},"2027-05",{"name":208,"class":49},"University of Chile",2,{"id":211,"slug":212,"hasResults":12,"nctId":213,"briefTitle":214,"officialTitle":215,"acronym":216,"eligibilityCriteria":217,"healthyVolunteers":59,"sex":218,"minAge":219,"maxAge":18,"enrollmentInfo":220,"targetDuration":4,"studyType":23,"phases":222,"briefSummary":224,"conditions":225,"keywords":4,"overallStatus":201,"whyStopped":4,"lastUpdateSubmitDate":235,"lastUpdatePostDateStruct":236,"startDateStruct":237,"completionDateStruct":238,"leadSponsor":239,"locationsCount":50},"100646025","phase-3-micronutrient-enhancement-for-development-and-health-in-adolescents---the-medha-study-100646025","NCT07695883","Micronutrient Enhancement for Development and Health in Adolescents - The MEDHA Study","Micronutrient Enhancement for Development and Health in Adolescents","MEDHA","Inclusion Criteria:\n\n* Unmarried 10-18 year old females\n* living in their parental home in the study area\n\nExclusion Criteria:\n\n* Married females under 18 years old;\n* those with a history or diagnosis of chronic or congenital heart disease, chronic kidney or lung disease, cancer, and epilepsy","FEMALE","10 Years",{"count":221,"type":22},3000,[223],"PHASE3","MEDHA is a randomized controlled trial among 10-18 year old girls to examine the use-case of the United Nations International Multiple Micronutrient Antenatal Preparation (UNIMMAP) multiple micronutrient supplement (MMS) formulation and to test an enhanced regimen (MMS+) with additional nutrients, vs. weekly iron-folic acid as standard of care on outcomes of neurodevelopment, linear growth, biochemical status, bone health, and other functional and health outcomes. This study is an individually randomized, open-label, three-arm trial of 3,000 participants supplemented for 12 months to assess the efficacy and safety of nutrient supplementation. Results of the study will inform the design of nutritional interventions and policy for this age group. In the context of the trial, the investigators will also do in-depth clinical and health assessments and collect biospecimens for a bio-archive for future deep-phenotyping of this population. This study will be conducted at the Johns Hopkins Bangladesh JiVitA field site in rural Gaibandha District of Bangladesh.",[226,227,228,229,230,231,232,29,233,234],"Neurodevelopment Outcome","Linear Growth","Micronutrient Status","Bone Mineral Density","Underweight","Stunting","Body Composition","HRQOL (Health Related Quality Of Life)","Waist-to-height Ratio","2026-08-03",{"date":137,"type":42},{"date":141,"type":22},{"date":143,"type":22},{"name":240,"class":49},"Johns Hopkins Bloomberg School of Public Health",{"id":242,"slug":243,"hasResults":12,"nctId":244,"briefTitle":245,"officialTitle":246,"acronym":4,"eligibilityCriteria":247,"healthyVolunteers":59,"sex":17,"minAge":60,"maxAge":248,"enrollmentInfo":249,"targetDuration":4,"studyType":23,"phases":251,"briefSummary":252,"conditions":253,"keywords":4,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":256,"lastUpdatePostDateStruct":257,"startDateStruct":259,"completionDateStruct":261,"leadSponsor":263,"locationsCount":50},"100610584","potatoes-type-2-diabetes-and-cardiometabolic-health-100610584","NCT07229482","Potatoes, Type 2 Diabetes, and Cardiometabolic Health","Cardiometabolic Effects of a Potato-rich Diet in Older Adults at Increased Risk of Developing Type 2 Diabetes: A Randomized Controlled Feeding Study","Inclusion Criteria:\n\n* Age 50-70 years\n* Weight stable for previous 3 months (±5% body weight)\n* Sedentary to recreationally active\n* ADA-Risk Screener questionnaire score of at least 5\n* No plans to gain or lose weight or change physical activity level\n* Willing to pick up food daily and consume foods provided for a 14-week period\n* Verbal and written informed consent\n* Estrogen or testosterone use, lipid-lowering or blood pressure medication and thyroid replacement medication is acceptable, if on stable dose for \\>6 months\n\nExclusion Criteria:\n\n* Body mass index \\>40 m2\u002Fkg\n* Diabetes or diabetes medication\n* Weight loss medication or medication influencing glucose metabolism\n* Antibiotic, prebiotic or probiotic use in prior 3 months\n* TCHOL \\>6.2 mmol\u002FL; TG \\>4.5 mmol\u002FL\n* Blood pressure (BP) \\> 159\u002F99 mmHg\n* Diagnosed inflammatory bowel disease\n* Past or current heart diseases, stroke, respiratory disease, endocrine or metabolic disease, or hematological-oncological disease\n* Vegetarian or vegan\n* Pregnant or plans to become pregnant\n* Food allergies or aversions to diet foods provided\n* Estrogen or testosterone usage, lipid-lowering medication, blood pressure medication usage \\\u003C6 months","70 Years",{"count":250,"type":22},42,[25],"Type 2 diabetes (T2D) is a major chronic health condition which increases risk of coronary artery disease, frailty, cognitive decline, and mortality. Additionally, hypertension is a major comorbidity for individuals with T2D, further increasing the risk of adverse cardiovascular outcomes. The prevalence of both conditions increases with advancing age. There is an urgent need to identify new approaches to prevent the development of T2D and improve cardiometabolic health in older adults 50-70 years of age.\n\nWhole white potatoes are an unprocessed food rich in essential nutrients often under-consumed by Americans, including potassium, fiber, magnesium, vitamins C and B6, and phytochemicals. Each of these nutrients individually are associated with cardiometabolic health benefits. Potatoes account for a significant amount of the intake of these nutrients in the US diet and are well-positioned to be a foundational element of a healthy dietary pattern. However, there are few interventional studies evaluating the effect of potatoes on cardiometabolic health, and the evidence from observational studies is mixed, leaving a significant gap in knowledge regarding the potential for potatoes to be included in healthy dietary patterns.\n\nThe results of our proposed study will provide foundational data that inform future dietary guidelines regarding the inclusion of white potatoes as part of a healthy US dietary pattern.",[254,29,255],"T2D","Cardiometabolic Health","2026-07-31",{"date":258,"type":42},"2026-08-04",{"date":260,"type":22},"2026-08",{"date":262,"type":22},"2029-03",{"name":264,"class":49},"Virginia Polytechnic Institute and State University",{"id":266,"slug":267,"hasResults":12,"nctId":268,"briefTitle":269,"officialTitle":269,"acronym":270,"eligibilityCriteria":271,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":272,"enrollmentInfo":273,"targetDuration":4,"studyType":23,"phases":275,"briefSummary":276,"conditions":277,"keywords":278,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":280,"lastUpdatePostDateStruct":281,"startDateStruct":283,"completionDateStruct":285,"leadSponsor":287,"locationsCount":50},"100506445","reducing-air-pollution-exposure-to-lower-blood-pressure-among-new-york-city-public-housing-residents-100506445","NCT05874479","Reducing AIR Pollution Exposure to Lower Blood PRESSURE Among New York City Public Housing Residents","AirPressureNYC","Inclusion Criteria:\n\n* self-reported nonsmokers living in a nonsmoking household.\n* adults living with hypertension (HTN) from NYC public housing.\n\nExclusion Criteria:\n\n* History of major known arrhythmias (e.g. atrial flutter or fibrillation, ventricular tachycardia).\n* Screening systolic BP ≥160 mm Hg or diastolic BP ≥100 mm Hg (i.e. severe hypertension by the 2017 ACC\u002FAHA BP guideline).\n* A change in drug regimen in the prior 2 weeks or a planned change in drug regimen during the first 30 days for those taking antihypertensive medication.\n* Current smoking or living with an active smoker who smokes indoors\n* Planned travel out of NYC for ≥2 weeks in next 6 months\n* Incarcerated\n* Pregnant\n* Unable\u002Funwilling to consent\n* Established cardiovascular disease\n* End-stage renal disease (chronic kidney disease stage IV or on dialysis)\n* Barrier to technology use (e.g., visual or hearing impairment)\n* Lung disease requiring oxygen\n* Cancer receiving treatment","100 Years",{"count":274,"type":22},440,[25],"Fine particulate matter \\\u003C2.5 µm (PM2.5) air pollution is the fifth leading risk factor for global mortality, with the largest portion of deaths due to cardiovascular disease (CVD). While several mechanisms are responsible, PM2.5-induced elevations in blood pressure (BP) may be relevant. Indoor portable air cleaners (PACs) are a novel approach to reduce exposure to PM2.5 and potentially lower blood pressure. The current study is being conducted to provide evidence that PACs reduce PM2.5 exposure and lower systolic blood pressure (SBP) in key patient populations.",[29],[279],"self-measured morning home systolic blood pressure (AM H-SBP)","2026-07-28",{"date":282,"type":42},"2026-07-29",{"date":284,"type":42},"2023-12-20",{"date":286,"type":22},"2028-03",{"name":288,"class":49},"NYU Langone Health",{"id":290,"slug":291,"hasResults":12,"nctId":292,"briefTitle":293,"officialTitle":293,"acronym":4,"eligibilityCriteria":294,"healthyVolunteers":59,"sex":17,"minAge":18,"maxAge":295,"enrollmentInfo":296,"targetDuration":4,"studyType":23,"phases":298,"briefSummary":299,"conditions":300,"keywords":302,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":304,"lastUpdatePostDateStruct":305,"startDateStruct":306,"completionDateStruct":308,"leadSponsor":310,"locationsCount":50},"100630572","impact-of-sleep-restriction-on-blood-pressure-reactivity-100630572","NCT07489417","Impact of Sleep Restriction on Blood Pressure Reactivity","Inclusion Criteria:\n\n* Healthy adult men and women\n* 18-45 years of age\n* BMI \\\u003C 25 kg\u002Fm² (normal weight group) or ≥ 30 kg\u002Fm² (obesity group)\n* Non-pregnant, non-breastfeeding, and non-nicotine users\n* Self-reported history of normal sleep duration (7-9 hours\u002Fnight) and bedtime prior to midnight\n* Premenopausal\n\nExclusion Criteria:\n\n* No acute or chronic conditions\n* Taking no medications known to affect sleep, autonomic, metabolic, or cardiovascular function\n* Self-reported history of irregular sleep\n* Self-reported history of hepatic, renal, pulmonary, cardiovascular, or neurological disease, stroke or neurovascular disease, bleeding\u002Fclotting disorders, sleep apnea or other sleep disorders, diabetes, history of alcoholism or substance abuse, major cardiovascular event or surgical procedure within the past three months, or hypertension","45 Years",{"count":297,"type":22},45,[25],"The purpose of the research study is to examine the effects of shortened sleep on blood pressure.",[301,29],"Sleep",[301,303],"Blood pressure","2026-07-24",{"date":280,"type":42},{"date":307,"type":42},"2026-03-04",{"date":309,"type":22},"2027-08",{"name":311,"class":49},"University of Missouri-Columbia",{"id":313,"slug":314,"hasResults":12,"nctId":315,"briefTitle":316,"officialTitle":317,"acronym":318,"eligibilityCriteria":319,"healthyVolunteers":59,"sex":17,"minAge":320,"maxAge":321,"enrollmentInfo":322,"targetDuration":4,"studyType":23,"phases":324,"briefSummary":326,"conditions":327,"keywords":4,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":329,"lastUpdatePostDateStruct":330,"startDateStruct":332,"completionDateStruct":334,"leadSponsor":336,"locationsCount":50},"100325189","early-phase-1-autonomic-control-of-the-circulation-and-vdr-100325189","NCT03513770","Autonomic Control of the Circulation and VDR","Autonomic Control of the Circulation and the Venous Distension Reflex","VDR","Inclusion Criteria\n\n* Are capable of giving informed consent\n* Are any race or ethnicity\n* Are fluent in written and spoken English\n* Have a satisfactory history and physical exam to meet inclusion\u002Fexclusion criteria\n* Are free of acute or chronic medical conditions\n* Are 21 - 35 years of age (inclusive)\n* Weigh over 50 kg\n\nExclusion Criteria\n\n* Are less than 21 or over 35 years of age\n* Are Pregnant or nursing women\n* Are prisoners or institutionalized individuals or unable to consent\n* Any chronic diseases (hypertension, heart, lung, neuromuscular disease, kidney disease, diabetes or cancer).\n* Are taking medications that may affect their cardiovascular or nervous system\n* Has taken an NSAID within 48 hours of any visit (visit will need to be rescheduled)\n* Has never taken NSAIDs and therefore would not know if they are allergic to it\n* Have a supine BP \\>140\u002F90 mmHg\n* Have known allergy to ibuprofen-like drugs (NSAIDS) or aspirin\n* Have history of asthma or nasal polyps\n* Have history of GI bleeding or ulcers\n* Subjects with ferromagnetic metal implants\n* Subjects who are claustrophobic","21 Years","35 Years",{"count":323,"type":22},18,[325],"EARLY_PHASE1","The study objective of this project is to examine the mechanisms of the venous distension reflex (VDR) in humans. We hypothesize that COX blockade with ketorolac tromethamine, an intravenous NSAID, will attenuate the muscle sympathetic nerve activity (MSNA) response to limb venous distension. To gain further insight into whether the COX byproducts directly stimulate chemically-sensitive afferents, or enable venodilation and indirectly evoke afferent stimulation, we will measure vein size using 3T MRI during venous distention with and without ketorolac infusions.",[328,29],"Venous Distension Reflex","2026-07-08",{"date":331,"type":42},"2026-07-09",{"date":333,"type":42},"2019-08-14",{"date":335,"type":22},"2027-11-01",{"name":337,"class":49},"Milton S. Hershey Medical Center",{"id":339,"slug":340,"hasResults":12,"nctId":341,"briefTitle":342,"officialTitle":342,"acronym":343,"eligibilityCriteria":344,"healthyVolunteers":59,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":345,"targetDuration":4,"studyType":23,"phases":347,"briefSummary":348,"conditions":349,"keywords":350,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":329,"lastUpdatePostDateStruct":352,"startDateStruct":353,"completionDateStruct":355,"leadSponsor":356,"locationsCount":50},"100323886","the-venous-distension-reflex-and-orthostatic-hypertension-100323886","NCT03496792","The Venous Distension Reflex and Orthostatic Hypertension","OH","Inclusion Criteria:\n\n* Are capable of giving informed consent\n* Are of any race or ethnicity\n* Are fluent in written and spoken English\n* Whose history and physical exam did not uncover any exclusion criteria\n* Are 18 years of age\n\nFor subjects with elevated standing BP\n\n* Systolic BP (SBP) during standing is at least 10 mmHg \\> the supine SBP\n* Patients with a diagnosis of stage I hypertension without other chronic diseases may be INCLUDED\n\nFor normal subjects without elevated standing BP\n\n* The change in SBP by standing is within ± 5 mmHg from the supine SBP\n* Matched gender, similar age and BMI (within 10%) to participants with elevated standing BP\n* Free of acute or chronic medical conditions\n\nExclusion Criteria:\n\n* Age \\\u003C 18 years of age\n* Are a pregnant or nursing woman\n* Are a prisoner or institutionalized individual or unable to consent\n* Have chronic diseases (e.g. heart, lung, neuromuscular disease, or cancer) other than stage I hypertension\n* Have orthostatic hypotension or a history of syncope\n* Current smoker\n* History of blood clots",{"count":346,"type":22},30,[25],"This research is being done to find out whether distension of veins in legs will cause a rise in blood pressure (orthostatic hypertension).",[29],[351],"venous distension reflex",{"date":331,"type":42},{"date":354,"type":42},"2020-03-10",{"date":335,"type":22},{"name":337,"class":49},{"id":358,"slug":359,"hasResults":12,"nctId":360,"briefTitle":361,"officialTitle":362,"acronym":4,"eligibilityCriteria":363,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":364,"targetDuration":4,"studyType":23,"phases":366,"briefSummary":367,"conditions":368,"keywords":4,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":370,"lastUpdatePostDateStruct":371,"startDateStruct":373,"completionDateStruct":375,"leadSponsor":376,"locationsCount":50},"100645954","nibp-accuracy-study-for-adult-subject-populations-100645954","NCT07697950","NIBP Accuracy Study for Adult Subject Populations","Non-Invasive Blood Pressure Accuracy Study for Adult Subject Populations","Inclusion Criteria:\n\n1. Age requirement: 18 and over.\n2. Have an upper limb (right OR left side) that fits the cuff size of the device (circumference ranging 17 cm to 40 cm) OR have a thigh (right OR left side) that fits a cuff size of the device (circumference ranging 38 to 50 cm).\n3. Have an arterial line as a standard of care, which measures blood pressure at the aortic root.\n4. Able to provide written informed consent.\n5. Expected to remain in the unit for the duration of the study procedure.\n\nExclusion Criteria:\n\n1. Have previously participated in this study (no subject may participate more than once).\n2. Pregnant and lactating women per site standard of care.\n3. Subjects with peripheral arterial diseases (causing left\u002Fright arm difference)\n4. Hemodynamically unstable subjects at the discretion of the investigator.\n5. Exhibited injuries, deformities, intravenous lines, or other abnormalities that, in the opinion of the Investigator, may prevent proper cuff application or functioning.\n6. Are suffering from infection(s) or immunocompromised patients that require isolation.\n7. PI or designee decision due to subject health conditions",{"count":365,"type":22},130,[25],"The purpose of this study is to collect NIBP and invasive aortic pressure data from the clinical setting.",[369,29],"Blood Pressure Measurement","2026-07-07",{"date":372,"type":42},"2026-07-13",{"date":374,"type":42},"2025-01-13",{"date":80,"type":22},{"name":377,"class":120},"GE Healthcare",{"id":379,"slug":380,"hasResults":12,"nctId":381,"briefTitle":362,"officialTitle":362,"acronym":4,"eligibilityCriteria":363,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":382,"targetDuration":4,"studyType":23,"phases":383,"briefSummary":367,"conditions":384,"keywords":4,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":370,"lastUpdatePostDateStruct":385,"startDateStruct":386,"completionDateStruct":388,"leadSponsor":390,"locationsCount":50},"100643127","non-invasive-blood-pressure-accuracy-study-for-adult-subject-populations-100643127","NCT07628296",{"count":365,"type":22},[25],[29,369],{"date":329,"type":42},{"date":387,"type":42},"2026-05-19",{"date":389,"type":22},"2027-06-30",{"name":377,"class":120},{"id":392,"slug":393,"hasResults":12,"nctId":394,"briefTitle":395,"officialTitle":396,"acronym":397,"eligibilityCriteria":398,"healthyVolunteers":59,"sex":17,"minAge":18,"maxAge":248,"enrollmentInfo":399,"targetDuration":4,"studyType":23,"phases":401,"briefSummary":402,"conditions":403,"keywords":406,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":370,"lastUpdatePostDateStruct":410,"startDateStruct":411,"completionDateStruct":413,"leadSponsor":414,"locationsCount":209},"100514489","effectiveness-and-adoption-of-the-teltex4bp-intervention-among-adults-with-hypertension-in-nepal-100514489","NCT05979168","Effectiveness and Adoption of the TelTex4BP Intervention Among Adults With Hypertension in Nepal","Effectiveness and Adoption of the Structured mHealth Intervention for Improving Blood Pressure Control (TelTex4BP) Among Adults With Hypertension in Nepal: A Randomized Controlled Trial","TelTex4BP","Inclusion Criteria:\n\n* Clinical diagnosis of hypertension\n* Currently receiving\u002Fprescribed blood pressure-lowering medication for more than three months\n* With uncontrolled blood pressure (\\>130\u002F80mm of Hg)\n* Should have access to a mobile phone\n* Able to read text messages ( by themselves\u002Fwith the help of family)\n\nExclusion Criteria:\n\n* Diagnosed with myocardial infarction, stroke, and kidney failure\n* Severe mental illness, cognitive impairment\n* Pregnant women or in the postpartum period",{"count":400,"type":22},500,[25],"Despite evidence of preventing cardiovascular disease (CVD) risk through lifestyle changes, many patients with hypertension (HTN) do not comply with this and suffer from CVD and other complications. A previous study using a structured lifestyle intervention program has reported a 14% decrease in the 10-year risk of developing CVD at one year among hypertensive and diabetes patients. Low and Middle-Income countries (LMICs) struggle with a shortage of health workers to deliver such interventions. In this context, mobile phones can contribute to bridging this gap by incorporating them into the health system for health intervention delivery. There is a need to develop contextual mHealth intervention adapted to local needs and culture and test its effectiveness in LMIC settings like Nepal. Our previous small-scale pilot mHealth (text messages) study reported promising evidence in reducing blood pressure among hypertensive patients in the intervention arm \\[adjusted reduction in systolic blood pressure (BP) -6.50 (95% CI, -12.6; -0.33) and diastolic BP -4.60 (95% CI, -8.16; -1.04)\\], with a greater proportion achieving target BP (70% vs 48% in the control arm, p = 0.006)\\] and improving treatment compliance (p \\\u003C 0.001) in Nepal. This finding supports the expansion to a large-scale trial of a structured mHealth intervention to see its long-term effectiveness and sustainability for patients with HTN to improve BP control and reduce CVD risk. Hence, this study aims to assess the effectiveness of a behavioural intervention through mHealth (telephone\u002Fmobile phone calls and text messages) informed by the RE-AIM framework for improving blood pressure control among patients with hypertension in a hospital (Manamohan Cardiothoracic Vascular and Transplant Center) of Kathmandu, Nepal.",[68,404,29,405],"Medication Adherence","Cardiovascular Diseases",[407,408,68,409],"Mobile Intervention","Blood Pressure Control","Randomized Controlled Trial",{"date":329,"type":42},{"date":412,"type":42},"2025-11-02",{"date":80,"type":22},{"name":415,"class":49},"Central Department of Public Health",{"id":417,"slug":418,"hasResults":12,"nctId":419,"briefTitle":420,"officialTitle":421,"acronym":4,"eligibilityCriteria":422,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":423,"targetDuration":4,"studyType":23,"phases":425,"briefSummary":426,"conditions":427,"keywords":4,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":428,"lastUpdatePostDateStruct":429,"startDateStruct":430,"completionDateStruct":432,"leadSponsor":434,"locationsCount":50},"100609591","the-continuity-study-100609591","NCT07216573","The Continuity Study","Continuous Blood Pressure Monitoring During Outpatient Surgery","Inclusion Criteria:\n\n1. Signed informed consent\n2. Age ≥ 18 years\n3. American Society of Anesthesiologists (ASA) Physical Status ≥ 2\n4. Scheduled for elective noncardiac surgery with intermittent arterial blood pressure monitoring using oscillometric arm cuff\n\nExclusion Criteria:\n\n1. Patient who is known to be pregnant\n2. Patient with existing or planned arterial pressure catheter\n3. Patient in whom systolic arterial pressure differs by more than 20 mmHg between the right and left arms\n4. Inability to place oscillometric cuff on the subject's upper extremity\n5. Extreme contraction of the smooth muscle in the arteries and arterioles of the lower arm and hand, such as may be present in patients with Raynaud's disease\n6. Finger or hand deformity that prevents proper placement of finger cuff by visual inspection\n7. Inability to place finger cuffs due to subject anatomy, condition, or obstructive paraphernalia (such as false nails)",{"count":424,"type":22},188,[25],"A before and after interventional cohort study comparing intermittent blood pressure measurement using the oscillometric arm cuff to continuous noninvasive blood pressure (cNIBP) measurement using the VitaWave finger cuffs in subjects undergoing elective surgery in an outpatient setting.",[29],"2026-07-06",{"date":329,"type":42},{"date":431,"type":42},"2026-05-07",{"date":433,"type":22},"2027-02",{"name":435,"class":120},"Becton, Dickinson and Company",{"id":437,"slug":438,"hasResults":12,"nctId":439,"briefTitle":440,"officialTitle":441,"acronym":4,"eligibilityCriteria":442,"healthyVolunteers":12,"sex":17,"minAge":295,"maxAge":4,"enrollmentInfo":443,"targetDuration":4,"studyType":23,"phases":445,"briefSummary":446,"conditions":447,"keywords":4,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":428,"lastUpdatePostDateStruct":448,"startDateStruct":449,"completionDateStruct":451,"leadSponsor":453,"locationsCount":50},"100553950","personal-bp---cai-study-100553950","NCT06492746","Personal BP - CAI Study","Assessing for Personalized Blood Pressure Targets During Cardiopulmonary Bypass With the Proprietary Cerebral Adaptive Index: A Pilot Investigation","Inclusion Criteria:\n\n1. Signed informed consent\n2. Age ≥ 45 years\n3. Planned cardiac surgery with Cardiopulmonary Bypass (CPB)\n4. Planned monitoring with ForeSight sensor and HemoSphere monitor\n5. Planned arterial catheterization for blood pressure monitoring\n6. High risk for cerebral vascular disease, defined as: a history of hypertension, pulse pressure \\> 60 mmHg, diabetes, stroke, transient ischemic attack, carotid bruit, tobacco smoking, or peripheral vascular disease\n\nExclusion Criteria:\n\n1. Non-English speaking\n2. Confirmed to be pregnant\n3. Surgery for congenital heart defect\n4. Non-availability of HemoSphere with laptop CAI interface",{"count":444,"type":22},120,[25],"A single-center, prospective, observational pilot of the Cerebral Adaptive Index for assessing personalized blood pressure targets",[29],{"date":329,"type":42},{"date":450,"type":42},"2024-06-03",{"date":452,"type":22},"2027-01",{"name":435,"class":120},{"id":455,"slug":456,"hasResults":12,"nctId":457,"briefTitle":458,"officialTitle":458,"acronym":459,"eligibilityCriteria":460,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":461,"targetDuration":463,"studyType":464,"phases":4,"briefSummary":465,"conditions":466,"keywords":467,"overallStatus":201,"whyStopped":4,"lastUpdateSubmitDate":471,"lastUpdatePostDateStruct":472,"startDateStruct":473,"completionDateStruct":475,"leadSponsor":477,"locationsCount":4},"100646622","blood-pressure-measured-on-the-arm-with-different-layers-of-clothing-versus-on-the-bare-arm-in-patients-at-grenoble-alpes-university-hospital-100646622","NCT07687771","Blood Pressure Measured on the Arm With Different Layers of Clothing Versus on the Bare Arm in Patients at Grenoble Alpes University Hospital","PA-COUCHE","Inclusion Criteria:\n\n* Patient over 18 years admitted to the emergency department of Grenoble University Hospital\n* No objection by the subject to the study\n* Affiliated to the French social security system (or equivalent)\n\nExclusion Criteria:\n\n* Physical inability to collect BP at the admission in the emergency department (pain, arm wound)\n* Technical inability to collect BP at the admission in the emergency department (incompatible size of the cuffs)\n* Medical or surgical contraindication to repeated blood pressure measurement on both arms\n* Patient who received antihypertensive treatment within the hour prior to measurements\n* Unable to communicate or non-french speaking patients or those with impaired comprehension or consciousness\n* Protected persons referred to in articles L1121-6 and L1121-8 of French public health code (deprived of liberty, tutorship or curatorship)\n* The patient already enrolled in the study",{"count":462,"type":22},161,"1 Day","OBSERVATIONAL","Blood pressure (BP) is an essential physiological parameter for assessing patient condition. In pre-hospital emergency situations it is measured at the arm over the patient's clothing when the patient cannot be undressed.\n\nHowever there is no study proving the reliability of this measurement compared to measurement according to recommendations (blood pressure cuff).\n\nThis lack of proof could lead to misinterpretation when measurement conditions are not optimal.",[29],[468,469,470],"Blood Pressure measurement","Bar Arm","Sleeve","2026-06-30",{"date":370,"type":42},{"date":474,"type":22},"2026-08-01",{"date":476,"type":22},"2027-01-30",{"name":478,"class":49},"University Hospital, Grenoble",{"id":480,"slug":481,"hasResults":12,"nctId":482,"briefTitle":483,"officialTitle":484,"acronym":4,"eligibilityCriteria":485,"healthyVolunteers":12,"sex":17,"minAge":4,"maxAge":18,"enrollmentInfo":486,"targetDuration":4,"studyType":23,"phases":488,"briefSummary":489,"conditions":490,"keywords":4,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":491,"lastUpdatePostDateStruct":492,"startDateStruct":493,"completionDateStruct":495,"leadSponsor":497,"locationsCount":209},"100646970","nibp-study-for-neonate-and-pediatric-subject-populations-100646970","NCT07684885","NIBP Study for Neonate and Pediatric Subject Populations","Non-Invasive Blood Pressure Accuracy Study for Neonate and Pediatric Subject Populations","Inclusion Criteria:\n\n* Age requirement: 0 to \\\u003C 18 years.\n* For children under 15 years old: Has a guardian or other legal representative who is able to provide consent of a guardian OR\n* For children between the age of 15-17 years; able to provide written consent form and the legal guardians can be reached to be informed of the study participation.\n* Have an upper limb (right OR left side) that fits the cuff size of the device (circumference ranging 3 cm to 33 cm) OR have a thigh (right OR left side) that fits a cuff size of the device (circumference ranging 38 to 50 cm).\n* Have an arterial line as a standard of care, which measures invasive blood pressure.\n* Expected to remain in the unit for the duration of the study procedure.\n\nExclusion Criteria:\n\n* Have previously participated in this study (no subject may participate more than once).\n* Subjects with peripheral arterial diseases (causing left\u002Fright arm difference).\n* Hemodynamically unstable subjects Subjects with complications on vasoactive agents at discretion of the Investigator.\n* Exhibited injuries, deformities, intravenous lines, or other abnormalities that, in the opinion of the Investigator, may prevent proper cuff application or functioning.\n* Are suffering from infection(s) or immunocompromised subjects that require isolation.\n* For adolescents of child-bearing potential, who are currently pregnant, suspected to be pregnant, or are currently lactating.\n* PI, designee or caring physician decision due to subject health conditions",{"count":487,"type":22},110,[25],"The purpose of this study is developing new NIBP enhancement and test it in clinical environment with neonates and children population subjects.",[29,369],"2026-06-29",{"date":428,"type":42},{"date":494,"type":42},"2025-05-14",{"date":496,"type":22},"2026-12-31",{"name":377,"class":120},{"id":499,"slug":500,"hasResults":12,"nctId":501,"briefTitle":502,"officialTitle":503,"acronym":504,"eligibilityCriteria":505,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":128,"enrollmentInfo":506,"targetDuration":4,"studyType":23,"phases":508,"briefSummary":509,"conditions":510,"keywords":517,"overallStatus":201,"whyStopped":4,"lastUpdateSubmitDate":523,"lastUpdatePostDateStruct":524,"startDateStruct":525,"completionDateStruct":527,"leadSponsor":529,"locationsCount":50},"100644654","impact-of-transcutaneous-spinal-stimulation-on-blood-pressure-and-orthostasis-in-spinal-cord-injury-100644654","NCT07674511","Impact of Transcutaneous Spinal Stimulation on Blood Pressure and Orthostasis in Spinal Cord Injury","Impact of Transcutaneous Spinal Stimulation on Blood Pressure and Orthostasis in Spinal Cord Injury: Short and Long-Term Effects","(SCI)","Inclusion Criteria:\n\n* Individuals with a SCI ≥ 1 year after injury\n* Injury level ≥ T6 (thoracic level)\n* AIS grade A-C\n* Cardiovascular dysfunction characterized by one or more of the following:\n\n  1. Persistent hypotension (SBP \\\u003C 90mmHg)\n  2. Orthostatic hypotension (OH, a drop of 20\u002F10 mmHg in SBP\u002FDBP within 5 minutes of standing\u002Fupright positioning).\n\nAdditionally, experiencing orthostatic symptoms in daily life and\u002For requiring medication to manage OH.\n\nExclusion Criteria:\n\n* Current illness (e.g., infection, a pressure injury that might interfere with the intervention)\n* Ventilator-dependent\n* History of implanted brain\u002Fspine\u002Fnerve stimulators\n* Cardiac pacemaker\u002Fdefibrillator or intra-cardiac lines\n* Significant coronary artery or cardiac conduction disease, a recent history of myocardial infarction\n* History of seizures\n* pregnancy\n* Insufficient mental capacity to understand and independently provide consent\n* Deemed unsuitable by the study physician",{"count":507,"type":22},10,[25],"The purpose of this study is to learn whether stimulation applied to the spinal cord through the skin (called transcutaneous spinal stimulation) can help control blood pressure in people with a spinal cord injury.\n\nThe main questions this study attempts to solve:\n\n1. What are the immediate effects of spinal cord transcutaneous stimulation on BP?\n2. Does stimulation produce lasting improvements in BP regulation and subsequently, daily function?",[511,30,512,513,405,514,515,516,29],"Spinal Cord Injuries","Orthostatic Hypotension","Spinal Cord Diseases","Trauma, Nervous System","Central Nervous System Disease","Nervous System Diseases",[518,519,520,521,522],"transcutaneous spinal cord stimulation","spinal stimulations","orthostatic hypotension","blood pressure","neuromodulation","2026-06-24",{"date":491,"type":42},{"date":526,"type":22},"2026-09",{"date":528,"type":22},"2028-12",{"name":530,"class":49},"Kessler Foundation",{"id":532,"slug":533,"hasResults":12,"nctId":534,"briefTitle":535,"officialTitle":536,"acronym":537,"eligibilityCriteria":538,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":539,"targetDuration":4,"studyType":23,"phases":541,"briefSummary":542,"conditions":543,"keywords":544,"overallStatus":201,"whyStopped":4,"lastUpdateSubmitDate":550,"lastUpdatePostDateStruct":551,"startDateStruct":553,"completionDateStruct":555,"leadSponsor":557,"locationsCount":50},"100642680","monitoring-blood-pressure-at-home-and-pharmacy-telehealth-100642680","NCT07623291","Monitoring Blood Pressure at Home and Pharmacy Telehealth","REmote Blood Pressure Monitoring and Pharmacist-Led Telehealth Program in an Emergency Department Transitional Care Clinic","REMAP-BP","Inclusion Criteria:\n\n* Age ≥18 years\n* Ability to speak English\n* Seen at UAB's or TGH's Emergency Department-Transitional Care Clinic\n* Blood pressure at Emergency Department-Transitional Care Clinic: Systolic BP ≥ 130 mmHg or Diastolic BP ≥ 80 mmHg\n* Have a cellphone with video capability\n\nExclusion Criteria:\n\n* Systolic BP ≥ 160 mmHg or Diastolic BP ≥ 100 mmHg (i.e. severe range hypertension (HTN) by the 2025 American College of Cardiology\u002FAmerican Heart Association BP guidelines) as they typically are referred to immediate treatment intensification. Since the prevalence of severe HTN is low (i.e.\\\u003C5%) in the US population, exclusion of these individuals will have only a small effect on the study.)\n* Lack of willingness or inability to provide written informed consent\n* Individuals who work overnight or second shift\n* History of known major arrhythmias\n* Currently pregnant or breastfeeding\n* Arm circumference \\>50 cm. \\*The upper limit for the largest BP cuff for oscillometric BP devices is typically 50-52 cm; data from the National Health and Nutrition Examination Survey, 2011-2016 indicated that \\\u003C1% of US adults have an arm circumference \\>50 cm, so this will have minimal effect on our study.",{"count":540,"type":22},420,[25],"The overall goal of this project is to determine if measuring blood pressure at home and staying in contact with a team of pharmacists and physicians to manage participants' blood pressure is useful. The study will enroll 400 participants who are seen at the University of Alabama at Birmingham Emergency Department - Transitional Care Clinic and Tampa General Hospital -Transitional Care Clinic. Half of the participants (200 patients) will be asked to measure blood pressure at home, and half of the participants (200 patients) will continue to receive usual care. Participants who measure blood pressure at home will also meet with a pharmacist weekly over the phone to discuss blood pressure readings and have blood pressure medications prescribed if needed. This program will last 6 months.",[68,29],[405,545,546,547,548,549],"Delivery of Health Care","Patient Care Management","Health Services Administration","Telemedicine","Vascular Diseases","2026-06-11",{"date":552,"type":42},"2026-06-15",{"date":554,"type":22},"2027-04-01",{"date":556,"type":22},"2031-01",{"name":169,"class":49},{"id":559,"slug":560,"hasResults":12,"nctId":561,"briefTitle":562,"officialTitle":563,"acronym":564,"eligibilityCriteria":565,"healthyVolunteers":59,"sex":17,"minAge":566,"maxAge":567,"enrollmentInfo":568,"targetDuration":4,"studyType":23,"phases":569,"briefSummary":570,"conditions":571,"keywords":573,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":576,"lastUpdatePostDateStruct":577,"startDateStruct":579,"completionDateStruct":581,"leadSponsor":583,"locationsCount":50},"100642665","multidimensional-sleep-health-intervention-for-couples-100642665","NCT07603245","Multidimensional Sleep Health Intervention for Couples","DREAM-COUPLES: A Dyadic Multidimensional Sleep Health Intervention","DREAM-COUPLES","Inclusion Criteria:\n\n* Adults aged 30-65 years\n* English-speaking\n* Systolic blood pressure greater than or equal to 120 mmHg (at minimum one individual in dyad)\n* Sub-optimal sleep health (at minimum short\u002Flong sleep duration and\u002For irregular sleep patterns)\n\nExclusion Criteria:\n\n* Optimal sleep health\n* History of cardiovascular disease or cancer\n* Not cognitively able to complete study requirements\n* Known medical conditions that would prevent them from safely participating in the study (severe psychiatric disorders, neurological degenerative disease, substance abuse\u002Fdependence)\n* History of severe depression or high risk of sleep apnea\u002Fuse of a Continuous Positive Airway Pressure (CPAP) device\n* Inability to provide informed consent","30 Years","65 Years",{"count":21,"type":22},[25],"The goal of this pilot dyadic study is to adapt a multidimensional sleep health (MDSH) intervention, previously disseminated at the individual level, for relationship partners, determine whether it improves sleep health and aspects of cardiometabolic health, and understand the role of dyadic dynamics in intervention effects.\n\nCan a dyadic MDSH intervention improve sleep health and blood pressure (primary outcomes) in relationship partners?\n\nCan a dyadic MDSH intervention improve anthropometric markers of adiposity, psychosocial indicators, stress, dyadic adjustment and coping, self-rated health (secondary outcomes) in relationship partners?\n\nAs this is a single-arm study, there is no control group. All relationship partners will complete a three-tier screening process, attend two in-person visits to receive intervention materials, have blood pressure measured and sleep data collected using in-office and out-of-office monitors, participate in weekly check-in phone calls with research staff over the 8 weeks to support adherence and complete a voluntary follow-up phone call at 16 weeks to provide additional sleep health information. The multidimensional sleep health promotion intervention is based on evidence-based sleep hygiene education and established behavior change techniques and includes: report-back of sleep health profiles, S.M.A.R.T (specific, measurable, attainable, realistic, and timely) goal-setting and establishing a sleep health plan with a fixed sleep schedule, sleep health coaching and dyadic action planning, self-monitoring, virtual sleep hygiene education, motivational feedback, and addressing light and noise in the sleep environment. Mixed methods will be used to understand implementation metrics, processes, and outcomes to establish the successful completion and future expansion of the intervention within this context.",[29,301,572],"Cardiovascular Health",[29,301,572,574,575],"Couples","Dyads","2026-06-10",{"date":578,"type":42},"2026-06-12",{"date":580,"type":42},"2026-06-08",{"date":582,"type":22},"2027-06",{"name":584,"class":49},"Columbia University",{"id":586,"slug":587,"hasResults":12,"nctId":588,"briefTitle":589,"officialTitle":590,"acronym":4,"eligibilityCriteria":591,"healthyVolunteers":59,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":592,"targetDuration":4,"studyType":23,"phases":594,"briefSummary":595,"conditions":596,"keywords":599,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":605,"lastUpdatePostDateStruct":606,"startDateStruct":607,"completionDateStruct":609,"leadSponsor":610,"locationsCount":50},"100569106","community-based-implementation-of-adapted-stac-100569106","NCT06689930","Community-based Implementation of Adapted STAC","Dissemination and Implementation of a Community-driven Approach to Improve the Health of Women, Infants, and Families: Pre-implementation Phase to Adapt Staying Healthy After Childbirth (STAC)","Inclusion Criteria (Interviews and Focus Groups):\n\n* Belong to the STAC-CAB or Lived Experience Group\n* Aged 18 or older\n\nInclusion Criteria (CBO Staff):\n\n* Staff of CBO participating in PDSA cycle\n* Aged 18 years or older\n\nInclusion Criteria (PDSA-Cycles):\n\n* Pregnant persons greater than or equal to 24 weeks gestation and prior to delivery or postpartum\n* Self-Identify as African American or Black\n* Aged 18 years or older\n* Capable of providing informed consent in English\n* Can follow M•care System use instructions in English\n* Have ownership of a functioning and reliable smartphone to upload and use the M•other App\n* Interested in preventing or managing blood pressure during pregnancy\n\nExclusion Criteria (PDSA-Cycles):\n\n* Persistent second or third trimester bleeding at time of enrollment\n* Premature rupture of membranes in the current pregnancy at time of enrollment\n* Known unrepaired maternal congenital heart disease requiring surgical correction\n* Maternal heart failure\n* Chronic kidney disease specifically requiring dialysis\n* On greater than two antihypertensive medications at time of enrollment",{"count":593,"type":22},46,[25],"This study is being done to adapt the Staying Healthy After Childbirth (STAC) intervention for implementation among Black Women and Birthing Persons (WBP).",[29,68,597,598],"Pregnancy Related","Health Equity",[600,601,602,603,29,604],"Prenatal","Post Partum","Hypertensive Disorders of Pregnancy","Remote Patient Monitoring","Community-Based Participation","2026-06-09",{"date":550,"type":42},{"date":608,"type":42},"2025-05-22",{"date":526,"type":22},{"name":611,"class":49},"University of Wisconsin, Madison",{"id":613,"slug":614,"hasResults":12,"nctId":615,"briefTitle":616,"officialTitle":617,"acronym":4,"eligibilityCriteria":618,"healthyVolunteers":12,"sex":218,"minAge":60,"maxAge":4,"enrollmentInfo":619,"targetDuration":4,"studyType":23,"phases":621,"briefSummary":623,"conditions":624,"keywords":629,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":633,"lastUpdatePostDateStruct":634,"startDateStruct":636,"completionDateStruct":638,"leadSponsor":640,"locationsCount":50},"100607902","phase-2-equol-and-vascular-function-in-women-with-chronic-kidney-disease-100607902","NCT07194590","Equol and Vascular Function in Women With Chronic Kidney Disease","Equol Supplementation for Improving Vascular Function in Postmenopausal Women With CKD","Inclusion Criteria:\n\n* Postmenopausal women\n* Aged ≥50 years\n* CKD stage 3 or 4 (eGFR with the CKD-EPI 2021 race-free equation: 15-59 mL\u002Fmin\u002F1.73m2; stable renal function in the past 3 months)\n* Low habitual intake of soy (soy-related food intake \\\u003C 2 times per week assessed by Soy-Specific Food Frequency Questionnaire)\n* Weight stable in the prior 3 months (\\\u003C2 kg weight change) and willing to remain weight stable throughout the study\n* Ability to provide informed consent.\n\nExclusion Criteria:\n\n* Patients with advanced CKD requiring chronic dialysis\n* Uncontrolled hypertension in CKD group (BP \\>140\u002F90 mmHg)\n* Use of any hormone replacement therapy\n* Allergy and\u002For intolerance to soy or soy-based products\n* Aspartate aminotransferase (AST), alanine aminotransferase (ALT), or total bilirubin values 2X upper limit of normal range (upper limit of normal range AST: 117 U\u002FL; ALT: 52 U\u002FL; total bilirubin: 1.3 mg\u002FdL)\n* History of breast cancer\n* Significant co-morbid conditions with a life expectancy of \\\u003C 1 year\n* Current tobacco or nicotine use or history of use in the last 12 months\n* History of kidney transplant\n* History of severe congestive heart failure (i.e., ejection fraction \\\u003C35%)\n* History of hospitalization within the last month\n* Immunosuppressant agents taken in the past 12 months\n* Known malignancy",{"count":620,"type":22},74,[622],"PHASE2","The risk of cardiovascular disease (CVD) is significantly elevated in patients with chronic kidney disease (CKD). Notably, women with CKD commonly experience menstrual disturbances induced by CKD, which may contribute to impaired vascular function and elevated CVD risk. However, most of the literature in nephrology focuses on male patients, and studies on women's vascular health are limited. Establishing effective therapies for improving vascular function and reducing CVD risk in women with CKD is a high research priority of the NIH.\n\nEquol contributes to improvement in vascular function, mediated in part by its anti-oxidative and anti-inflammatory properties. However, there is no information on the effect of equol on vascular function in women with CKD. The proposed project aims to determine the effect of 12 weeks of oral equol supplementation on vascular function in postmenopausal women with CKD.",[625,626,627,628,29],"Chronic Kidney Disease (Stage 3-4)","Vascular Function","Cognitive Functions","Cerebrovascular Function",[630,409,631,632,626],"S-equol","Chronic Kidney Disease","Women's Health","2026-06-01",{"date":635,"type":42},"2026-06-02",{"date":637,"type":42},"2026-02-19",{"date":639,"type":22},"2030-11-30",{"name":641,"class":49},"University of Colorado, Denver",{"id":643,"slug":644,"hasResults":12,"nctId":645,"briefTitle":646,"officialTitle":647,"acronym":4,"eligibilityCriteria":648,"healthyVolunteers":59,"sex":17,"minAge":566,"maxAge":4,"enrollmentInfo":649,"targetDuration":4,"studyType":23,"phases":651,"briefSummary":652,"conditions":653,"keywords":4,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":654,"lastUpdatePostDateStruct":655,"startDateStruct":657,"completionDateStruct":659,"leadSponsor":660,"locationsCount":50},"100538064","the-dream-study-a-multidimensional-sleep-health-intervention-for-improving-cardiometabolic-health-100538064","NCT06285968","The DREAM Study: A Multidimensional Sleep Health Intervention for Improving Cardiometabolic Health","Addressing Sleep Duration, Regularity, and Efficiency: A Multidimensional Sleep Health Intervention for Improving Cardiometabolic Health (The DREAM Study)","Inclusion Criteria:\n\n* Adults aged 30+ years\n* English or Spanish speaking\n* Systolic blood pressure greater than or equal to 120 mmHg\n* Sub-optimal sleep health\n* No history of overt cardiovascular disease\n* No history of cancer\n\nExclusion Criteria:\n\n* Optimal sleep health\n* History of cardiovascular disease or cancer\n* Non-English or non-Spanish speaking\n* Not cognitively able to complete study requirements\n* Severe psychiatric disorders\n* Inability to provide informed consent",{"count":650,"type":22},200,[25],"The purpose of this randomized clinical trial is to evaluate the impact of a multidimensional sleep health promotion intervention on blood pressure, glycemic control indicators, anthropometric markers of adiposity, and lifestyle factors in adults. Participants will be randomized into an intervention or a control group. The control arm will receive standard Life's Essential 8 cardiovascular health educational materials. The intervention arm will additionally receive a multi-component intervention aimed at improving sleep health based on evidence-based sleep hygiene education and established behavior change techniques that include personalized sleep health feedback, goal setting and establishing a sleep health plan, coaching, self-monitoring, and addressing light and noise in the sleep environment. Mixed methods will be used to understand implementation determinants, processes, and outcomes, ensuring the successful completion and future expansion of this intervention.",[29],"2026-05-27",{"date":656,"type":42},"2026-05-29",{"date":658,"type":42},"2024-03-12",{"date":389,"type":22},{"name":584,"class":49}]